Not the comfy chair! Cancer drugs that act against multiple active sites

References

• Klaeger S, Heinzlmeir S, Wilhelm M, et al. The target landscape of clinical kinase drugs. Science. 2017;358:pii: eaan4368.
   PubMed Web of Science ®Google Scholar
• Muttathukattil AN, Srinivasan S, Halder A, et al. Role of guanidinium-carboxylate ion interaction in enzyme inhibition with implication for drug design. J Phys Chem B. 2019 Oct 9;123: 9302–9311.
   Web of Science ®Google Scholar
• Dobrydnev AV, Tkachuka TM, Atamaniuka VP, et al. Quercetin-amino acid conjugates are promising anti-cancer agents in drug discovery projects. Mini Rev Med Chem. 2019 Oct 9;19. DOI:10.2174/1389557519666191009152007.
   Google Scholar
• Deeks ED. Neratinib: first global approval. Drugs. 2017;77:1695–1704.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5:835–844.
   PubMed Web of Science ®Google Scholar
• Inaba H, Panetta JC, Pounds S, et al. Sorafenib population pharmacokinetics and skin toxicities in children and adolescents with refractory/relapsed leukemia or solid tumor malignancies. Clin Cancer Res. 2019 Aug 27. pii: clincanres.0470.2019. doi: 10.1158/1078-0432.CCR-19-0470
   PubMedGoogle Scholar
• Strumberg D, Voliotis D, Moeller JG, et al. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther. 2002;40:580–581.
   PubMedGoogle Scholar
• Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer. 2005;92:1855–1861.
   PubMed Web of Science ®Google Scholar
• Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res. 2005;11:5472–5480.
   PubMed Web of Science ®Google Scholar
• Gavini J, Dommann N, Jakob MO, et al. Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinoma. Cell Death Dis. 2019;10:749.
   PubMed Web of Science ®Google Scholar
• Lin CH, Elkholy KH, Wani NA, et al. Ibrutinib potentiates anti-hepatocarcinogenic efficacy of sorafenib by targeting EGFR in tumor cells and BTK in immune cells in the stroma. Mol Cancer Ther. 2019 Oct 3. pii: molcanther.0135.2019. doi: 10.1158/1535-7163.MCT-19-0135
   Google Scholar
• Wang C, Wang H, Lieftink C, et al. CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma. Gut. 2019 Sep 13. pii: gutjnl-2019-318506. doi: 10.1136/gutjnl-2019-318506.
   Google Scholar
• Takimoto CH, Awada A. Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol. 2008;61:535–548.
   PubMed Web of Science ®Google Scholar
• Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007;12:426–437.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Schiller J, Schuchter LM, et al. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res. 2008;14:4836–4842.
   PubMed Web of Science ®Google Scholar
• Pan P, Wang L, Wang Y, et al. Systematic review and meta-analysis of -new-generation tyrosine kinase inhibitors versus imatinib for newly diagnosed chronic myeloid leukemia. Acta Haematol. 2019;12:1–13.
   Google Scholar
• Fondevila F, Méndez-Blanco C, Fernández-Palanca P, et al. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers. Exp Mol Med. 2019;51:109.
   PubMed Web of Science ®Google Scholar
• Lee ATJ, Jones RL, Huang PH. Pazopanib in advanced soft tissue sarcomas. Signal Transduct Target Ther. 2019;4:16.
   PubMed Web of Science ®Google Scholar
• Bæk MN, Budolfsen C, Grimm D, et al. Drug-induced hypertension caused by multikinase inhibitors (Sorafenib, sunitinib, lenvatinib and axitinib) in renal cell carcinoma treatment. Int J Mol Sci. 2019;20(19):4712. pii: E4712. doi: 10.3390/ijms20194712.
   Web of Science ®Google Scholar
• Brattås MK, Reikvam H, Tvedt THA, et al. Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Expert Opin Investig Drugs. 2019;28:411–420.
   PubMed Web of Science ®Google Scholar
• Gross-Goupil M, Kwon TG, Eto M, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol. 2018;29:2371–2378.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109.
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006;98:326–334.
   PubMed Web of Science ®Google Scholar
• Chiou JF, Tai CJ, Huang MT, et al. Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. Ann Surg Oncol. 2010;17:603–612.
   PubMed Web of Science ®Google Scholar
• Roberts JL, Tavallai M, Nourbakhsh A, et al. GRP78/Dna K is a target for nexavar/stivarga/votrient in the treatment of human malignancies, viral infections and bacterial diseases. J Cell Physiol. 2015;230:2552–2578.
   PubMed Web of Science ®Google Scholar
• Booth L, Shuch B, Albers T, et al. Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function. Oncotarget. 2016;7:12975–12996.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Tavallai M, et al. OSU-03012 and viagra treatment inhibits the activity of multiple chaperone proteins and disrupts the blood-brain barrier: implications for anti-cancer therapies. J Cell Physiol. 2015;230:1982–1998.
   PubMed Web of Science ®Google Scholar
• Rahmani M, Davis EM, Crabtree TR, et al. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol. 2007;27:5499–5513.
   PubMed Web of Science ®Google Scholar
• Park MA, Zhang G, Martin AP, et al. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther. 2008;7:1648–1662.
   PubMed Web of Science ®Google Scholar
• Zhu G, Lee AS. Role of the unfolded protein response, GRP78 and GRP94 in organ homeostasis. J Cell Physiol. 2015;230:1413–1420.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Ecroyd H, et al. AR-12 inhibits multiple chaperones concomitant with stimulating autophagosome formation collectively preventing virus replication. J Cell Physiol. 2016;231:2286–2302.
   PubMed Web of Science ®Google Scholar
• NCT00978523. Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma.
   Google Scholar
• Verheijen RB, Beijnen JH, Schellens JHM, et al. Clinical pharmacokinetics and pharmacodynamics of pazopanib: towards optimized dosing. Clin Pharmacokinet. 2017;56:987–997.
   PubMed Web of Science ®Google Scholar
• Masood A, Kancha RK, Subramanian J. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: focus on afatinib. Semin Oncol. 2019 Sep 11;46:271–283. pii: S0093-7754(18)30191-X.
   PubMed Web of Science ®Google Scholar
• Paranjpe R, Basatneh D, Tao G, et al. Neratinib in HER2-positive breast cancer patients. Ann Pharmacother. 2019;53:612–620.
   PubMed Web of Science ®Google Scholar
• Sooro MA, Zhang N, Zhang P. Targeting EGFR-mediated autophagy as a potential strategy for cancer therapy. Int J Cancer. 2018;143:2116–2125.
   PubMed Web of Science ®Google Scholar
• Liu Q, Yu S, Zhao W, et al. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018;17:53.
   PubMed Web of Science ®Google Scholar
• Moll HP, Pranz K, Musteanu M, et al. Afatinib restrains K-RAS-driven lung tumorigenesis. Sci Transl Med. 2018;10:eaao2301.
   PubMed Web of Science ®Google Scholar
• Yamaoka T, Ohmori T, Ohba M, et al. Distinct afatinib resistance mechanisms identified in lung adenocarcinoma harboring an EGFR mutation. Mol Cancer Res. 2017;15:915–928.
   PubMed Web of Science ®Google Scholar
• Ebert K, Mattes J, Kunzke T, et al. MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells. PLoS One. 2019;14:e0223225.
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Verma C, Guzman M, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 2009;28:803–814.
   PubMed Web of Science ®Google Scholar
• Collins DM, Gately K, Hughes C, et al. Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines. Cell Immunol. 2017;319:35–42.
   PubMed Web of Science ®Google Scholar
• Collins DM, Conlon NT, Kannan S, et al. Preclinical characteristics of the irreversible pan-HER kinase inhibitor neratinib compared with lapatinib: implications for the treatment of HER2-positive and HER2-mutated breast cancer. Cancers (Basel). 2019;11:737. pii: E737.
   Web of Science ®Google Scholar
• Cocco E, Javier Carmona F, Razavi P, et al. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). PLoS One. 2018;13:e0200836.
   PubMedGoogle Scholar
• Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A. 2005;102:7665–7670.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang J, Liu C, et al. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells. Sci Signal. 2018;11. pii: eaat9773. DOI:10.1126/scisignal.aat9773.
   Google Scholar
• Pal R, Wei N, Song N, et al. Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: treatment implications beyond KRAS mutations. PLoS One. 2018;13:e0200836.
   PubMed Web of Science ®Google Scholar
• Kruspig B, Monteverde T, Neidler S, et al. The ERBB network facilitates KRAS-driven lung tumorigenesis. Sci Transl Med. 2018;10:eaao2565. pii: eaao2565.
   PubMed Web of Science ®Google Scholar
• Tavallai M, Booth L, Roberts JL, et al. Rationally repurposing ruxolitinib (Jakafi (®)) as a solid tumor therapeutic. Front Oncol. 2016;6:142.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Tavallai M, et al. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. Oncotarget. 2016;7:19620–19630.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Poklepovic A, et al. HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo. Oncotarget. 2017;8:90262–90277.
   PubMedGoogle Scholar
• Davis MI, Hunt JP, Herrgard S, Ciceri P, et al.Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011;29:1046–1051.
   PubMed Web of Science ®Google Scholar
• Fuller SJ, McGuffin LJ, Marshall AK, et al. A novel non-canonical mechanism of regulation of MST3 (mammalian Sterile20-related kinase 3). Biochem J. 2012;442:595–610.
   PubMed Web of Science ®Google Scholar
• Klooster JP, Jansen M, Yuan J, et al. Mst4 and Ezrin induce brush borders downstream of the Lkb1/Strad/Mo25 polarization complex. Dev Cell. 2009;16:551–562.
   PubMed Web of Science ®Google Scholar
• Jang JW, Kim MK, Bae SC. Reciprocal regulation of YAP/TAZ by the hippo pathway and the small GTPase pathway. Small GTPases. 2018;20:1–9.
   Google Scholar
• Rawat SJ, Chernoff J. Regulation of mammalian Ste20 (Mst) kinases. Tr Biochem Sci. 2015;40:149–156.
   PubMed Web of Science ®Google Scholar
• Bae SJ, Luo X. Activation mechanisms of the hippo kinase signaling cascade. Biosci Rep. 2018;38. pii: BSR20171469. DOI:10.1042/BSR20171469.
   PubMed Web of Science ®Google Scholar
• Kong D, Zhao Y, Men T, et al. Hippo signaling pathway in liver and pancreas: the potential drug target for tumor therapy. J Drug Target. 2015;23:125–133.
   PubMed Web of Science ®Google Scholar
• Patel SH, Camargo FD, Yimlamai D. Hippo signaling in the liver regulates organ size, cell fate, and carcinogenesis. Gastroenterology. 2017;152:533–545.
   PubMed Web of Science ®Google Scholar
• Hergovich A. The roles of NDR protein kinases in hippo signalling. Genes (Basel). 2016;7:21. pii: E21.
   PubMed Web of Science ®Google Scholar
• Sharif AAD, Hergovich A. The NDR/LATS protein kinases in immunology and cancer biology. Semin Cancer Biol. 2018;48:104–114.
   PubMed Web of Science ®Google Scholar
• Bitra A, Sistla S, Mariam J, et al. Rassf proteins as modulators of Mst1 kinase activity. Sci Rep. 2017;7:45020.
   PubMed Web of Science ®Google Scholar
• Chen M, Zhang H, Shi Z, et al. The MST4-MOB4 complex disrupts the MST1-MOB1 complex in the hippo-YAP pathway and plays a pro-oncogenic role in pancreatic cancer. J Biol Chem. 2018;293:14455–14469.
   PubMed Web of Science ®Google Scholar
• Dent P, Booth L, Roberts JL, et al. Neratinib inhibits hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells. Oncogene. 2019;38:5890–5904.
   PubMed Web of Science ®Google Scholar
• Crawford JJ, Bronner SM, Zbieg JR. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review. Expert Opin Ther Pat. 2018;28:867–873.
   Web of Science ®Google Scholar
• Meng Z, Moroishi T, Mottier-Pavie V, et al. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the hippo pathway. Nat Commun. 2015;6:8357.
   PubMed Web of Science ®Google Scholar
• Hergovich A. Regulation and functions of mammalian LATS/NDR kinases: looking beyond canonical hippo signalling. Cell Biosci. 2013;3:32.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Rais R, et al. Neratinib augments the lethality of [regorafenib + sildenafil]. J Cell Physiol. 2019 Apr;234(4):4874–4997.
   PubMed Web of Science ®Google Scholar
• Thompson BJ, Sahai E. MST kinases in development and disease. J Cell Biol. 2015;210:871–882.
   PubMed Web of Science ®Google Scholar
• Chen S, Fang Y, Xu S, et al. Mammalian Sterile20-like kinases: signalings and roles in central nervous system. Aging Dis. 2018;9:537–552.
   PubMed Web of Science ®Google Scholar
• Wang OH, Azizian N, Guo M, et al. Prognostic and functional significance of MAP4K5 in pancreatic cancer. PLoS One. 2016;11:e0152300.
   PubMed Web of Science ®Google Scholar
• Hsu CL, Lee EX, Gordon KL, et al. MAP4K3 mediates amino acid-dependent regulation of autophagy via phosphorylation of TFEB. Nat Commun. 2018;9:942.
   PubMed Web of Science ®Google Scholar
• Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322:764–774.
   PubMed Web of Science ®Google Scholar
• Kim RY, Sterman DH, Haas AR. Malignant mesothelioma: has anything changed? Semin Respir Crit Care Med. 2019;40:347–360.
   PubMed Web of Science ®Google Scholar
• Frederickson AM, Arndorfer S, Zhang I, et al. Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis. Immunotherapy. 2019;11:407–428.
   PubMed Web of Science ®Google Scholar
• Racanelli AC, Rothbart SB, Heyer CL, et al. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res. 2009;69:5467–5474.
   PubMed Web of Science ®Google Scholar
• Rothbart SB, Racanelli AC, Moran RG. Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas. Cancer Res. 2010;70:10299–10309.
   PubMed Web of Science ®Google Scholar
• Brooks HB, Meier TI, Geeganage S, et al. Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine models. Sci Rep. 2018;8:15458.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Poklepovic A, et al. PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. Oncotarget. 2017;8:1449–1468.
   PubMedGoogle Scholar
• Tripathi DN, Chowdhury R, Trudel LJ, et al. Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1. Proc Natl Acad Sci U S A. 2013;110:E2950–7.
   PubMed Web of Science ®Google Scholar
• Alers S, Wesselborg S, Stork B. ATG13: just a companion, or an executor of the autophagic program? Autophagy. 2014;10:944–956.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Poklepovic A, et al. [pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells. Cancer Biol Ther. 2017;18:705–714.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Poklepovic A, et al. HDAC inhibitors enhance the immunotherapy response of melanoma cells. Oncotarget. 2017;8:83155–83170.
   PubMedGoogle Scholar
• Booth L, Roberts JL, Poklepovic A, et al. Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody. Cancer Biol Ther. 2019;20:109–121.
   PubMed Web of Science ®Google Scholar
• Mohanty R, Chowdhury CR, Arega S, et al. CAR T cell therapy: a new era for cancer treatment (Review). Oncol Rep. 2019. DOI:10.3892/or.2019.7335.
   PubMedGoogle Scholar
• Leonetti A, Wever B, Mazzaschi G, et al. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resist Updat. 2019;46:100644.
   PubMed Web of Science ®Google Scholar
• Terranova-Barberio M, Thomas S, Ali N, et al. HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Oncotarget. 2017;8:114156–114172.
   PubMedGoogle Scholar
• Dent P, Booth L, Poklepovic A, et al. Signaling alterations caused by drugs and autophagy. Cell Signal. 2019;64:109416.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Kirkwood J, et al. Unconventional approaches to modulating the immunogenicity of tumor cells. Adv Cancer Res. 2018;137:1–15.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Sander C, et al. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget. 2017;8:16367–16386.
   PubMedGoogle Scholar
• Booth L, Roberts JL, Tavallai M, et al. [Pemetrexed + zorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling. Oncotarget. 2016;7:23608–23632.
   PubMedGoogle Scholar
• Heidecker G, Huleihel M, Cleveland JL, et al. Mutational activation of c-raf-1 and definition of the minimal transforming sequence. Mol Cell Biol. 1990;10:2503–2512.
   PubMed Web of Science ®Google Scholar
• Booth L, Roberts JL, Rais R, et al. Palbociclib augments neratinib killing of tumor cells that is further enhanced by HDAC inhibition. Cancer Biol Ther. 2019;20:157–168.
   PubMed Web of Science ®Google Scholar